Safety, Tolerability, and Pharmacodynamics of the ADAMTS‐5 Nanobody M6495: Two Phase 1, Single‐Center, Double‐Blind, Randomized, Placebo‐Controlled Studies in Healthy Subjects and Patients With Osteoarthritis

Safety, Tolerability, and Pharmacodynamics of the ADAMTS‐5 Nanobody M6495: Two Phase 1, Single‐Center, Double‐Blind, Randomized, Placebo‐Controlled Studies in Healthy Subjects and Patients With Osteoarthritis

Objective To assess the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple injections of M6495, a disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS‐5)  nanobody, in healthy volunteers and patients with osteoarthritis. Methods Two randomized, placebo‐...

Full description

Bibliographic Details
Main Authors: Asger Reinstrup Bihlet, Torben Balchen, Kosalaram Goteti, Jesper Sonne, Christoph Ladel, Morten Asser Karsdal, Victor Ona, Flavie Moreau, Roseann Waterhouse, Anne‐Christine Bay‐Jensen, Hans Guehring
Format: Article
Language:English
Published: Wiley 2024-04-01
Series:ACR Open Rheumatology
Online Access:https://doi.org/10.1002/acr2.11610

Internet

https://doi.org/10.1002/acr2.11610

Similar Items